Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Significance of overexpression of alpha methylacyl-coenzyme A racemase in hepatocellular carcinoma.

Li W, Cagle PT, Botero RC, Liang JJ, Zhang Z, Tan D.

J Exp Clin Cancer Res. 2008 May 15;27:2. doi: 10.1186/1756-9966-27-2.

2.

Role of alpha methylacyl-coenzyme A racemase in differentiating hepatocellular carcinoma from dysplastic and nondysplastic liver cell lesions.

Helal Tel A, Radwan NA, Abdel Kader Z, Helmy NA, Hammad SY.

Ann Diagn Pathol. 2012 Oct;16(5):330-4. doi: 10.1016/j.anndiagpath.2012.01.003. Epub 2012 Apr 25.

PMID:
22542076
3.

AMACR is not applicable as a diagnostic tool in hepatocellular carcinoma.

Willemoe GL, Vainer B.

APMIS. 2010 Feb;118(2):85-90. doi: 10.1111/j.1600-0463.2009.02564.x.

PMID:
20132171
4.

Alpha-methylacyl-CoA racemase (AMACR/P504S) can distinguish hepatocellular carcinoma and dysplastic hepatocytes from benign nondysplastic hepatocytes.

Guzman G, Wu SJ, Kajdacsy-Balla A, Cotler SJ.

Appl Immunohistochem Mol Morphol. 2006 Dec;14(4):411-6.

PMID:
17122637
5.

Overexpression of α-methylacyl-CoA racemase is associated with CTNNB1 mutations in hepatocellular carcinomas.

Sekine S, Ogawa R, Ojima H, Kanai Y.

Histopathology. 2011 Apr;58(5):712-9. doi: 10.1111/j.1365-2559.2011.03798.x. Epub 2011 Apr 4.

PMID:
21457159
6.

α-Methylacyl-CoA racemase (AMACR) serves as a prognostic biomarker for the early recurrence/metastasis of HCC.

Xu B, Cai Z, Zeng Y, Chen L, Du X, Huang A, Liu X, Liu J.

J Clin Pathol. 2014 Nov;67(11):974-9. doi: 10.1136/jclinpath-2014-202378. Epub 2014 Aug 4.

7.

Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance.

Lin A, Weiser MR, Klimstra DS, Paty PB, Tang LH, Al-Ahmadie H, Hoo Park S, Guillem JG, Temple L, Wong WD, Gerald WL, Shia J.

Hum Pathol. 2007 Jun;38(6):850-6. Epub 2007 Apr 18.

PMID:
17442371
9.

Alpha-methylacyl coenzyme A racemase overexpression in gallbladder carcinoma confers an independent prognostic indicator.

Wu LC, Chen LT, Tsai YJ, Lin CM, Lin CY, Tian YF, Sheu MJ, Uen YH, Shiue YL, Wang YH, Yang SJ, Wu WR, Li SH, Iwamuro M, Kobayasshi N, Huang HY, Li CF.

J Clin Pathol. 2012 Apr;65(4):309-14. doi: 10.1136/jclinpath-2011-200489. Epub 2012 Jan 21.

PMID:
22267983
11.

A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma.

Jiang Z, Fanger GR, Banner BF, Woda BA, Algate P, Dresser K, Xu J, Reed SG, Rock KL, Chu PG.

Cancer Detect Prev. 2003;27(6):422-6.

PMID:
14642549
12.
14.

Activation of Akt-mTOR-p70S6K pathway in angiogenesis in hepatocellular carcinoma.

Li W, Tan D, Zhang Z, Liang JJ, Brown RE.

Oncol Rep. 2008 Oct;20(4):713-9.

PMID:
18813808
17.

Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.

Jiang Z, Fanger GR, Woda BA, Banner BF, Algate P, Dresser K, Xu J, Chu PG.

Hum Pathol. 2003 Aug;34(8):792-6.

PMID:
14506641
18.

Increased expression of α-methylacyl-coenzyme A racemase (AMACR; p504s) and p16 in distal hyperplastic polyps.

Dayi N, Baba HA, Schmid KW, Schmitz KJ.

Diagn Pathol. 2013 Oct 23;8:178. doi: 10.1186/1746-1596-8-178.

19.

Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S).

Jiang Z, Woda BA, Wu CL, Yang XJ.

Am J Clin Pathol. 2004 Aug;122(2):275-89. Review.

PMID:
15323145
20.

Supplemental Content

Support Center